Riboxin (IDP), an orally administered purine derivative known as hypoxanthine riboside, exhibits antihypoxic and antihyperthermic effects. Furthermore, it demonstrates antiarrhythmic properties in cats, rabbits, and mice suffering from Ouabain-induced cardiac rhythm abnormalities. Additionally, Riboxin offers protection to animals from the harmful consequences of γ-irradiation [1] [2].

Riboxin administered orally at a single dose of 250 mg/kg increased swimming time in mice without significantly affecting strength endurance. Under the same conditions, Riboxin enhanced the survival rate of animals in a heat chamber trial [1]. When given orally at 50 mg/kg once daily for six days, Riboxin extended the ambulation time in mice but did not significantly alter swimming or running times [1]. Additionally, a pre-experimental 250 mg/kg oral dose of Riboxin provided significant protection against γ irradiation in mice [1].